Alpro Group and AstraZeneca Collaborate to Advance Early Detection Across the Cardio-Kidney-Metabolic Spectrum and Raise Awareness of Hyperkalemia
4 Articles
4 Articles
Alpro Group and AstraZeneca Collaborate to Advance Early Detection Across the Cardio-Kidney-Metabolic Spectrum and Raise Awareness of Hyperkalemia
Nationwide #AreYourKidneysOK+? initiative expands access to subsidised blood screening, public education, and pharmacist support for 12,550 Malaysians.
Alpro Group partners with AstraZeneca for kidney screening initiative
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 19 August 2026 – As chronic conditions such as diabetes, cardiovascular disease and chronic kidney disease continue to affect Malaysians, early detection is becoming increasingly important in reducing complications and improving long-term health outcomes. (From left: Dr. Cheng Yong Fatt (Consultant Nephrologist of KPJ Seremban Specialist Hospital); Dr. Svetlana Yanchuk (Country President of Astr…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium








